Phase II Trial of Allovectin-7® for Metastatic Melanoma
Completed · Phase 2
Conditions studied: Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer
In brief
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
Key facts
- Study ID
- NCT00044356
- Run by
- Vical
- People needed
- 133
- Starts
- 2001-02-01
- Expected to finish
- 2004-09-01
- Last updated by the study team
- 2011-07-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Cancer Center — Tucson, Arizona, United States
- University of Arkansas Cancer Research Center — Little Rock, Arkansas, United States
- Comprehensive Blood and Cancer Center — Bakersfield, California, United States
- University of California, San Francisco — San Francisco, California, United States
- University of Colorado Cancer Center — Denver, Colorado, United States
- Oncology Specialists, S.C. — Park Ridge, Illinois, United States
- Louisiana State University Medical Center — New Orleans, Louisiana, United States
- Hematology Oncology Associates of Baltimore — Baltimore, Maryland, United States
- North Memorial Health Care — Robbinsdale, Minnesota, United States
- Mayo Clinic — Rochester, Minnesota, United States
- The Melanoma Center of Saint Louis — St Louis, Missouri, United States
- Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
- Beth Israel Medical Center — New York, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Cancer Care Alliance — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.